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Cross-talk between tumour and stromal cells can profoundly influence cancer cell invasion by increasing the availability of mitogenic
peptides such as endothelin-1 (ET-1). Endothelin-1 is elevated in men with metastatic prostate cancer (PC), and can exert both an
autocrine (epithelial) and a paracrine (stromal) influence on growth. Endothelin-1 is generated from its inactive precursor big-ET-1 by
endothelin-converting enzyme 1 (ECE-1). We and others have demonstrated that ECE-1 expression is significantly elevated in
tumours and surrounding stromal tissue. Our current data show siRNA-mediated knockdown of stromal ECE-1 reduces epithelial
(PC-3) cell invasion in coculture. Interestingly, readdition of ET-1 only partially recovers this effect suggesting a novel role for ECE-1
independent of ET-1 activation. Parallel knockdown of ECE-1 in both stromal and epithelial compartments results in an additive
decrease in cell invasion. We extrapolated this observation to the four recognised isoforms ECE-1a, ECE-1b, ECE-1c and ECE-1d.
Only ECE-1a and ECE-1c were significant but with reciprocal effects on cell invasion. Transient ECE-1c overexpression increased
PC-3 invasiveness through matrigel, whereas transient ECE-1a expression suppressed invasion. Furthermore, transient ECE-1a
expression in stromal cells strongly counteracts the effect of transient ECE-1c expression in PC-3 cells. The ECE-1 isoforms may,
therefore, be relevant targets for antiinvasive therapy in prostate and other cancers.
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Alteration of interactions between the epithelial and stromal
compartments can result in a loss of tissue homeostasis and
the induction of malignant epithelia. This, in turn, influences
adjacent stroma to generate a dynamically altered environment
providing factors for growth (Yang et al, 2005; Albini and Sporn,
2007). One such factor, endothelin-1 (ET-1), is evident in
prostatic tissue ex vivo (Godara et al, 2007). Endothelin-1 is
abnormally elevated in men with advanced metastatic prostate
cancer (PC) and contributes to the transition to androgen
independence (Nelson et al, 1995; Papandreou et al, 1998).
Endothelin-1 is generated from its inactive precursor big ET-1
by endothelin-converting enzyme 1 (ECE-1). We and others have
shown that ECE-1 expression is significantly elevated in tumours
(Ahmed et al, 2000; Eberl et al, 2000; Egidy et al, 2000b; Arun et al,
2001; Usmani et al, 2002; Dawson et al, 2004, 2006; Awano et al,
2005; Smollich et al, 2007). We have previously demonstrated
that ECE-1 is present in PC cell lines and primary tissues, and
is expressed at the cell surface and intracellularly (Dawson et al,
2004, 2006), with levels of ECE-1 elevated in primary malignant
stromal cells as compared with benign (Dawson et al, 2004). The
specific inhibition of endogenous ECE-1 activity in these stromal
cells significantly reduced epithelial cell invasion (Dawson et al,
2004).
Endothelin-converting enzyme 1 is a membrane-bound zinc
metalloprotease composed of a large extracellular or luminal
C-terminal catalytic domain, a transmembrane region and a small
N-terminal cytoplasmic domain. There are four distinct ECE-1
isoforms; ECE-1a (758 residues), ECE-1b (770) (Shimada et al,
1995); ECE-1c (754) (Schweizer et al, 1997) and ECE-1d (767)
(Valdenaire et al, 1999). These isoforms differ only in part of their
N-terminal cytoplasmic regions and are derived from a single gene
through the use of alternative promoters (Orzechowski et al, 1997).
They have similar catalytic properties but distinct subcellular
localisation and tissue distribution (Schweizer et al, 1997).
Endothelin-converting enzyme 1a and ECE-1c are localised at the
cell surface, whereas ECE-1b and ECE-1d are intracellular with
ECE-1b present in late endosomes or multivesicular bodies and
ECE-1d concentrated in recycling endosomes (Muller et al, 2003).
More recently, ECE-1 has been reported to regulate peptide
receptor recycling in endosomes through metabolism of the
peptide ligand (Roosterman et al, 2007). Endothelin-converting
enzyme 1c is the major isoform in terms of expression level and
tissue distribution (Schweizer et al, 1997). We have shown that
ECE-1c is the main isoform expressed in prostate epithelial cells,
with increased expression in metastatic, androgen-independent
cell lines (Dawson et al, 2006). ECE-1c is also the most abundant
isoform in lung cancer-derived cell lines (Ahmed et al, 2000).
Endothelin-converting enzyme 1 shares 40% homology with a
fellow member of the M13 family of endopeptidases, neprilysin
(NEP). Neprilysin is downregulated in metastatic human PC and
contributes to the transition to the androgen-independent disease
(Papandreou et al, 1998) both through catalytic and non-catalytic
signalling interactions. Neprilysin can affect signal trans-
duction pathways, which regulate cell migration (Sumitomo
et al, 2000) apoptosis (Sumitomo et al, 2004) and Akt-mediated
survival (Sumitomo et al, 2001), and has also been reported to
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sbe a tumour suppressor (Dai et al, 2001) directly associating with
PTEN (Sumitomo et al, 2004). Signalling capability, therefore, is
already recognised among the M13 family.
In this study, we have investigated the invasion of metastatic
epithelial cells with regard to ECE-1 isoform expression, and
herein provide the first evidence for distinct non-catalytic roles for
two of the ECE-1 isoforms, ECE-1a and ECE-1c, in promoting
and suppressing PC cell invasion, mediated through their unique
N-terminal regions.
MATERIALS AND METHODS
Materials
The ECE-1 monoclonal antibody AEC 32-236, as described by
(Shimada et al, 1994) was generously donated by Dr K Tanzawa
(Sankyo Research Laboratories, Tokyo, Japan). The polyclonal
antibody against the ECE-1c isoform is produced in-house as
described and characterised previously (Brown et al, 1998).
Primary prostate cells and the PNT1-a cell line were kindly
provided by Prof Norman Maitland, York Cancer Research
Unit, UK. Matrigel, cell culture inserts and companion plates
were obtained from BD Biosciences (Bedford, UK). The siGLOt
RISC-Free siRNA (non-targeting siRNA with a fluorescent label)
was purchased from Dharmacon via Perbio, Cramlington, UK.
The individual siRNA duplex targeting the ECE-1 sequence
(CTTCCACAGCCCCCGGAGT), common to all ECE-1 isoforms,
and the scramble (nonsense) control was custom synthesised by
Dharmacon. The pool siRNA containing four different oligonucleo-
tides targeted to the ECE-1 sequence was also synthesised
by Dharmacon. Endothelin-1 was purchased from Calbiochem
(Nottingham, UK).
Methods
Cell culture The PC-3 cells were routinely cultured in Ham’s F12
nutrient mix (BioWhittaker, Wokingham, UK) supplemented with
2m ML -glutamine and 7% (v/v) FBS. The PNT1-a cells and the
primary prostate stromal cells were maintained in RPMI-1640
(BioWhittaker, Wokingham, UK) containing 2mML-glutamine and
10% (v/v) FBS. Penicillin at 1% (v/v) and streptomycin (50Uml
 1)
were added to the primary stromal cell media. STO (mouse
embryonic fibroblast) cells were routinely cultured in Dulbecco’s
modified Eagle’s medium (DMEM; BioWhittaker, Wokingham,
UK) containing 2mML -glutamine and 10% (v/v) FBS. All
cells were routinely grown in antibiotic-free media at 371C and
5% CO2.
Construction of ECE-1 isoform expression plasmids Endothelin-
converting enzyme 1 isoforms were amplified from EA.hy926
(epithelial/endothelial hybrid cell line) RNA. Each isoform was
amplified by one-step RT-PCR using an isoform-specific forward
primer incorporating a unique Not 1 restriction site and a common
reverse primer incorporating a unique Xba 1 restriction site. The
amplified products were digested and ligated into the pcDNA3
mammalian expression vector (Invitrogen, Paisley, UK). Each
construct was fully sequenced for verification.
Lipid-mediated oligonucleotide transfection into adherent
mammalian cells Cells were seeded at 50% confluency and
transfected with siRNA duplexes (Dharmacon) using Oligofecta-
mine
t (Invitrogen, Paisley, UK) according to the manufacturer’s
guidelines. Cells were transfected with 100nM duplexes targeted to
ECE-1 or the control duplex siGLO
t.
Transient transfection of ECE-1 isoforms Cells at 60%
confluency were transfected with ECE-1a, ECE-1b, ECE-1c or
ECE-1d expression plasmids using FuGENE-6 (3:2 ratio of
FuGENE-6 to DNA; Roche, UK) according to the manufacturer’s
instructions.
Western blot analysis Protein was isolated from whole cell lysates
and resolved by SDS–PAGE, transferred to a nitrocellulose
membrane and blocked in 0.1% Tween-20 in 10mM Tris-HCl,
pH 7.4 (TBST) with 5 % (w/v) milk powder and 2% (w/v) BSA.
Membranes were incubated with anti-ECE-1 monoclonal (1:500)
or anti-ECE-1c polyclonal (1:500). Anti-b-actin (Sigma, Pool, UK;
1:10000) was used as a loading control. Immunoreactive bands
were visualised using enhanced chemiluminescence (ECL).
Immunofluorescence Cells were grown to 60% confluency on
sterile coverslips, washed twice with PBS and fixed and
permeabilised for 10min in methanol/acetone (1:1 ratio) at room
temperature. Non-specific binding sites were blocked for 30min in
blocking buffer (TBS, 1% (v/v) normal goat serum and 0.2% (w/v)
gelatin). Primary antibodies were used at the following concentra-
tions: ECE-1 monoclonal (1:50) and ECE-1c (1:100). For negative
controls, the primary antibody was replaced with preimmune
serum or IgG subclass antibody (Sigma, Poole, UK). Cells were
incubated for 30min at room temperature with FITC-conjugated
anti-mouse IgG (1:1000) or FITC-conjugated anti-rabbit IgG
(1:1000, Jackson ImmunoResearch Laboratory via Stratech
Scientific, Newmarket, UK) and counterstained using 40,6-Diami-
dino-2-phenylindole (DAPI; Sigma, Poole, UK). Cells were
examined using an Olympus IX70 inverted wide-field fluorescence
microscope. Images were captured using Delta Vision from
Applied Precision.
Invasion assay The invasion assay was performed essentially as
described by Dawson et al. (2004). Briefly, invasion chambers were
prepared using matrigel (250mgml
 1), which was added (200ml) to
cell culture inserts (8mm pore) and incubated overnight at 371C. In
parallel, STO cells or primary prostate stromal cells were seeded
into 24-well companion plates and incubated overnight at 371C.
On the following day, matrigel-coated inserts were placed in the
wells of the companion plates and PC-3 cells (2 10
5) in DMEM
0.1% (w/v) BSA were added to the insert. When ET-1 supplements
were required, they were added to both STO/stromal cell media
(companion plate) and epithelial cell media (insert). The invasion
assay was incubated overnight at 371C. Next day, the inserts were
removed from the wells, washed in PBS, fixed in 100% methanol
for 10min at room temperature and stained with 0.1% (w/v)
crystal violet (Sigma, Poole, UK). Cells that had invaded to the
underside of the inserts were counted by light microscopy. Four
fields of view from each insert were counted. The data distribution
was shown to be normal using the SPSS NPAR test, and therefore
two-tailed student T-tests were used to ascertain statistical
significance with a threshold of Po0.05.
RESULTS
Endothelin-converting enzyme 1 knockdown in either
stroma or epithelia can reduce cell invasion
To determine the effect of stromal ECE-1 depletion on invasion,
STO cells were transfected with either 100nM siRNA duplex
oligonucleotides targeted to ECE-1 (either custom-made duplexes
or a pool containing four different target sequences to eliminate
the possibility of off-target effects) or oligonucleotides with a non-
coding sequence (siGLO or scrambled sequence). The protein
expression of ECE-1 was measured at 24h by western blotting and
immunofluorescent analyses. Endothelin-converting enzyme 1
levels decreased 24h post-transfection (Figure 1A (i), (ii) and
(iii)). In siGLO or scramble transfected cells, no change was
observed. The influence of ECE-1 siRNA-treated STO cells, in
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scoculture, on PC-3 invasion through matrigel was subsequently
analysed (Figure 1A (iv)). STO cells harbouring siGLO had no
significant effect on PC-3 cell invasion. STO cells harbouring ECE-
1 siRNA caused a decrease to approximately 40% of control levels
in PC-3 cell invasion. Supplementation with ET-1 (1–100nM)
recovered cell invasion maximally to approximately 85% of control
levels (Figure 1A (iv)). In PC-3 cells, ECE-1 protein expression was
analysed by western blotting and immunofluorescence following
transfection with ECE-1 siRNA over a period of 72h. Endothelin-
converting enzyme 1 expression visibly decreased 72h post-
transfection (Figure 1B (i) and (ii)). The influence of ECE-1
depletion in the epithelial compartment (PC-3), in coculture with
untreated STO cells, was subsequently measured (Figure 1B (iii)).
The invasion of ECE-1-depleted PC-3 cells decreased by approxi-
mately 50%, when compared with control PC-3 cells (transfected
with siGLO). Supplementation with 1–100nM ET-1 recovered
invasion maximally to approximately 85% of control levels. To
examine the effect of ECE-1 depletion in both epithelial and
stromal compartments, the invasion of ECE-1-depleted PC-3 cells
was measured in the presence of ECE-1-depleted STO. Invasion
decreased to less than 20% of control levels (Figure 1C).
Endothelin-converting enzyme 1a and ECE-1c isoforms
suppress and promote invasion, respectively
To ascertain the effect on invasion of ECE-1 isoform expression in
the epithelial compartment, PC-3 cells were transiently transfected
with ECE-1a, ECE-1b, ECE-1c or ECE-1d, and invasion was
subsequently measured using the matrigel invasion assay. The
invasion of PC-3 cells transfected with ECE-1a decreased by
approximately 50% (relative to untreated control) in the presence
of untreated stromal cells, whereas the expression of ECE-1c
significantly increased PC-3 cell invasion by approximately 40% in
the presence of untreated stromal cells (Figure 2A). Transient
transfection of PC-3 cells with either ECE-1b or ECE-1d did not
significantly alter the invasion (Figure 2A).
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Figure 1 (A) Influence of ECE-1 siRNA expressed in stromal cells. STO cells were transfected with 100nM ECE-1 siRNA oligonucleotides targeted to
ECE-1 (either custom-made duplexes or a pool containing four different target sequences to eliminate the possibility of off-target effects) or oligonucleotides
with a non-coding sequence (siGLO or scrambled sequence) using oligofectamine and incubated for 24h. Samples were analysed using (i) western blotting:
lane 1, siGLO-treated STO cells; lane 2, custom-made siRNA duplex to ECE-1; (ii) lane 1, siGLO-treated STO cells; lane 2, siRNA ECE-1 pool or (iii)
immunofluorescence analysis. The polyclonal antibody to ECE-1 was used for the western blot analysis (1:500) and immunofluorescence (1:100). Anti-b-
actin (1:10,000) was used as a loading control for western blotting. (iv) Invasion of PC-3 cells was measured in the presence of the ECE-1 siRNA-treated
STO cells using a matrigel invasion assay. Endothelin-converting enzyme 1 siRNA STO cells were harvested 24h post-transfection and added to the lower
well of the invasion chamber. Endothelin-1- at 1–100nM was added to both the STO (lower well) and the PC-3 (upper well), and the assay was incubated
for 24h. Each bar represents the mean value of eight fields counted; *Po0.001. (B) Influence of ECE-1 siRNA expressed in epithelial cells. The PC-3 cells
were transfected with 100nM ECE-1 siRNA using oligofectamine and incubated 24–72h. siGLO siRNA was used as a negative control. Samples were
analysed using (i) western blotting: lane 1, siGLO-treated STO cells; lanes 2–4, siRNA ECE-1 24–72h or (ii) immunofluorescence analysis. The monoclonal
antibody to ECE-1 was used for western blot analysis (1:200) and immunofluorescence (1:50). Anti-b-actin (1:10000) was used as a loading control for
western blotting. (iii) Invasion of ECE-1 siRNA PC-3 cells was measured in the presence of the STO cells using a matrigel invasion assay. Endothelin–1 at 1–
100nM was added to both the STO (lower well) and the PC-3 (upper well), and the assay was incubated for 24h. Each bar represents the mean value of
eight fields counted; *Po0.001. (C) Influence of ECE-1 siRNA expressed in both stromal and epithelial cells. Both the PC-3 cells and the STO cells were
treated with siRNA ECE-1 and added to a matrigel invasion assay. Each bar represents the mean value of eight fields counted; *Po0.001.
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the stromal compartment, ECE-1a ECE-1b, ECE-1c or ECE-1d
isoforms were expressed in primary prostate stromal cells,
and invasion of PC-3 cells was subsequently measured in
coculture. Prostate cancer-3 cell invasion in the presence of
ECE-1a expressing stroma decreased by approximately 25%, but no
significant change was observed for the other isoforms (Figure 2B).
As only ECE-1a and ECE-1c significantly altered the invasion, all
subsequent experiments were carried out using these isoforms.
Endothelin-converting enzyme 1a isoform abrogates the
influence of ECE-1c isoform in cotransfection
To determine the effect of parallel ECE-1 isoform expression in the
epithelia and stroma, PC-3 cells were transfected with either ECE-
1a or ECE-1c, and their invasion was subsequently measured in the
presence of ECE-1a expressing stroma (Figure 3A). Endothelin-
converting enzyme 1a stroma in coculture with ECE-1a epithelia
significantly reduced cell invasion by approximately 65% (more
than in the presence of untreated stroma (Figure 2A)). Endothelin-
converting enzyme 1a stroma in coculture with ECE-1c epithelia
counter suppresses the cell invasion resulting in overall invasion
levels similar to control. The expression of ECE-1c in the stroma
had no effect on the invasion of ECE-1a or ECE-1c-transfected
PC-3 cells (Figure 3B).
Endothelin-converting enzyme 1c isoform can transform
low-invasive cells to cells with a highly invasive phenotype
PNT1-a, a low-invasive cell line (Lang et al, 2000; Dawson et al,
2004), which expresses negligible ECE-1 (Dawson et al, 2004)
was transiently transfected with the ECE-1 isoforms, and invasion
through matrigel was measured. Transient expression of ECE-1c
in PNT1-a cells increased invasion by 100% in the presence
of untreated stromal cells, compared with untransfected
PNT1-a (Figure 4). Cotransfection of ECE-1a and ECE-1c into
PNT1-a cells reduced this invasive margin to approximately 30 %
(Figure 4).
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Figure 3 The effect on invasion of ECE-1 isoforms expressed
concomitantly in the epithelial and stromal compartment. The PC-3 cells
were transfected with ECE-1a and ECE-1c isoforms using FuGENE-6.
Exogenous ECE-1 expression levels were determined using (A) western
blot analysis (monoclonal ECE-1 antibody); lane 1, PC-3 cells; lane 2, PC-3
cells expressing ECE-1a; lane 3, PC-3 cells expressing ECE-1c. These cells
were then used in a matrigel invasion assay in the presence of stroma
transfected with (B) ECE-1a or (C) ECE-1c. Each bar represents the mean
value of eight fields counted; *Po0.05.
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Figure 2 The effect of ECE-1 isoform expression in either the epithelial
or stromal compartment on invasion (A) PC-3 cells were transiently
transfected with ECE-1a, ECE-1b, ECE-1c and ECE-1d using FuGENE-6
transfection reagent. Following a 48-h incubation, the cells were harvested
and used in a matrigel invasion assay in the presence of stromal cells. Each
bar represents the mean value of eight fields counted; *Po0.001. (B)
Stromal cells were transfected with ECE-1a ECE-1b, ECE-1c and ECE-1d
using FuGENE-6 and incubated for 48h. Invasion of PC-3 cells was
measured in the presence of the ECE-1-transfected stromal cells using a
matrigel invasion assay. Each bar represents the mean value of eight fields
counted.
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cells can decrease cell invasion
To investigate whether the effects on cell invasion were mediated
by a soluble agent, the invasion of ECE-1a- and ECE-1c expressing
PC-3 cells was assessed using either media from normal stromal
cells or conditioned media from stromal cells transfected
with ECE-1a for 48h. In the presence of normal stromal media,
the invasion of ECE-1a expressing PC-3 cells decreased by
approximately 40% (relative to control), whereas the invasion of
ECE-1c expressing PC-3 cells increased by approximately 20%
(Figure 5). In the presence of conditioned (ECE-1a) stromal media,
the invasion of ECE-1a expressing PC-3 cells further decreased by
approximately 50% (relative to control). Interestingly, the invasion
of ECE-1c expressing PC-3 cells also decreased by approximately
40%, indicating the likely presence of a soluble invasion-
suppressing factor in the conditioned media.
DISCUSSION
Elevated ECE-1 levels are increasingly being correlated with
tumour progression in PC and other types of malignancies (Egidy
et al, 2000b; Arun et al, 2001; Dawson et al, 2004, 2006; Awano
et al, 2005; Smollich et al, 2007). We have previously recognised
the ability of ECE-1 to promote PC cell invasion in vitro (Dawson
et al, 2004). A specific chemical inhibitor of endogenous ECE-1
activity in stromal cells significantly reduced the ability of PC-3
cells to invade through matrigel as a consequence of reduced
levels of ET-1 peptide (Dawson et al, 2004). With respect to the
four recognised isoforms of ECE-1 (ECE-1a-d), ECE-1c is the only
isoform expressed in PC cells, with increased expression in
metastatic, androgen-independent cells (Dawson et al, 2006). This
study identified novel roles for two of the ECE-1 isoforms (ECE-1a
and ECE-1c) in the invasion process.
Initially, siRNA duplexes (non-isoform specific) targeted to
stromal or epithelial ECE-1 were successfully used to reduce
invasion with a dramatically greater reduction, if both compart-
ments were targeted simultaneously. Addition of exogenous
ET-1 only partially recovered this effect on invasion implicating
an alternative role for ECE-1 independent of ET-1 generation.
A unique role for ECE-1 has also been proposed by Berger et al
(2005) who demonstrated that ECE-1 inhibitors could inhibit
proliferation of human glioblastoma cells without reducing ET-1
levels (Berger et al, 2005). Endothelin-converting enzyme 1a
and ECE-1c isoforms were next transiently expressed in epithelial
(PC-3) and stromal (STO) cells to assess their influence on
invasion. Endothelin-converting enzyme 1c was the sole invasion-
promoting isoform, with overexpression resulting in a further
increase in the invasive capacity of PC-3 cells. More importantly,
this effect was reproducible with ECE-1c expressed either in the
epithelia or the stroma, indicating both an autocrine and paracrine
influence. Transient expression of ECE-1a, which is normally
absent from PC-3 and stromal cells, suppressed the invasion of
PC-3 cells. As with ECE-1c, this effect was also reproducible in
both epithelial and stromal compartments. More importantly, the
expression of ECE-1a in the stromal compartment counteracted
the invasion-promoting properties of ECE-1c expression in PC-3
cells, reflecting a property normally associated with suppressor
proteins, such as PTEN, p53 and NEP (Li et al, 1997; Sumitomo
et al, 2004).
Although ECE-1 has been reported in a number of cancers
(Ahmed et al, 2000; Egidy et al, 2000a, 2000b; Arun et al, 2001;
Usmani et al, 2002; Dawson et al, 2004, 2006; Awano et al, 2005;
Smollich et al, 2007), specific isoforms present have yet to be
identified. To our knowledge, ECE-1a expression has not been
reported in any cancer cells either in vitro or in vivo, and only
ECE-1c is abundant in prostate and lung cancer (Ahmed et al,
2000; Dawson et al, 2006). Given that the expression of each
isoform is regulated by distinct promoters, it is likely that different
stimuli may regulate each isoform differently. This hypothesis is
supported by the work of Orzechowski et al (2001) who
demonstrated that PKC activation by treatment with phorbol ester
resulted in the upregulation of ECE-1a expression, but had no
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Figure 4 The suppressive effect of ECE-1a isoform on invasion-
promoting properties of ECE-1c in the presence of stroma. PNT1-a cells
were transfected with the ECE-1c isoform using FuGENE-6. Exogenous
ECE-1 expression levels were determined using (A) western blot analysis
(monoclonal ECE-1 antibody); lane 1, PNT1-a cells; lane 2, PNT1-a cells
expressing ECE-1a; lane 3, PNT1-a cells expressing ECE-1c. These cells
were then used in a matrigel invasion assay in the presence of stroma. Each
bar represents the mean value of eight fields counted; *Po0.001.
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Figure 5 The effect of conditioned media from ECE-1a expressing
stromal cells on PC-3 invasion. Stromal cells were transfected with ECE-1a
using FuGENE-6 and incubated for 48h. The media from untreated stroma
and ECE-1a expressing stroma was collected and added to the lower well
of the invasion chamber. Prostate cancer-3 cells were transfected with
ECE-1a and ECE-1c, incubated for 48h and added to the upper well of the
invasion assay. Each bar represents the mean value of eight fields counted.
Influence of ECE-1 isoforms on cell invasion
LA Lambert et al
1118
British Journal of Cancer (2008) 99(7), 1114–1120 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
seffect on the other ECE-1 isoforms (Orzechowski et al, 2001). This
regulation was at the level of transcription involving the
transcription factor Ets-1, suggesting that the binding site for this
factor may not be present in the regulatory region of the other
isoform promoters.
Interestingly, in the presence of conditioned media from
ECE-1a-transfected stromal cells, the invasion of PC-3 cells was
compromised. Furthermore, ECE-1a-conditioned media also coun-
teracted the invasive ability of ECE-1c-transfected PC-3 cells,
suggesting the possibility of a soluble factor in the conditioned
media. One possibility is that it might be a soluble form of ECE-1a in
the media. A soluble secreted form of ECE-1 protein has recently
been reported (Kuruppu et al, 2007). Endothelin-converting enzyme
1, expressed endogenously in human umbilical vein endothelial
cells, is subject to constitutive ectodomain shedding, although the
secretase responsible is not identified (Kuruppu et al, 2007).
Alternatively, it is possible that the secreted ECE-1a can
form a heterodimer with ECE-1c at the cell surface, initiating
the internalisation of the ECE-1a/ECE-1c complex. Endothelin-
converting enzyme 1b has already been shown to form hetero-
dimers (Muller et al, 2003) with other ECE-1 isoforms, and acts as
a vehicle for regulating their distribution (Muller et al, 2003).
Given the known signalling capability of NEP, a close homologue
of ECE-1, it can be speculated that heterodimerisation of ECE-1
isoforms may trigger intracellular signalling. A similar mechanism
exists for other cell surface proteins, such as members of the ErbB
family (Zhan et al, 2006).
In conclusion, the exploitation of the ECE-1 isoforms may lead
to a new generation of molecular-targeted therapies for prostate
and other cancers.
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